{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T12:37:36Z","timestamp":1777293456329,"version":"3.51.4"},"reference-count":200,"publisher":"Bentham Science Publishers Ltd.","issue":"2","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CNSAMC"],"published-print":{"date-parts":[[2024,8]]},"abstract":"<jats:sec>\n<jats:title>Abstract:<\/jats:title>\n<jats:p>Alzheimer's disease (AD) is a debilitating form of dementia that primarily affects cholinergic\nneurons in the brain, significantly reducing an individual's capacity for learning and creative\nskills and ultimately resulting in an inability to carry out even basic daily tasks. As the elderly\npopulation is exponentially increasing, the disease has become a significant concern for society.\nTherefore, neuroprotective substances have garnered considerable interest in addressing this universal\nissue. Studies have shown that oxidative damage to neurons contributes to the pathophysiological\nprocesses underlying AD progression. In AD, tau phosphorylation and glutamate excitotoxicity\nmay play essential roles, but no permanent cure for AD is available. The existing therapies only\nmanage the early symptoms of AD and often come with numerous side effects and toxicities. To\naddress these challenges, researchers have turned to nature and explored various sources such as\nplants, animals, and marine organisms. Many historic holy books from different cultures emphasize\nthat adding marine compounds to the regular diet enhances brain function and mitigates its decline.\nConsequently, researchers have devoted significant time to identifying potentially active neuroprotective\nsubstances from marine sources. Marine-derived compounds are gaining recognition due to\ntheir abundant supply of diverse chemical compounds with biological and pharmacological potential\nand unique mechanisms of action. Several studies have reported that plants exhibit multitarget\npotential in treating AD. In light of this, the current study focuses on marine-derived components\nwith excellent potential for treating this neurodegenerative disease.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/0118715249269050231129103002","type":"journal-article","created":{"date-parts":[[2024,2,2]],"date-time":"2024-02-02T10:41:52Z","timestamp":1706870512000},"page":"166-181","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Marine-derived Compounds: A Powerful Platform for the Treatment of\nAlzheimer\u2019s Disease"],"prefix":"10.2174","volume":"24","author":[{"given":"Rashmi","family":"Arora","sequence":"first","affiliation":[{"name":"Chitkara College of Pharmacy, Chitkara University, Chandigarh, Punjab, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ritchu","family":"Babbar","sequence":"additional","affiliation":[{"name":"Chitkara College of Pharmacy, Chitkara University, Chandigarh, Punjab, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abhishek","family":"Dabra","sequence":"additional","affiliation":[{"name":"Guru Gobind Singh College of Pharmacy,\nYamunanagar, Haryana, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bhawna","family":"Chopra","sequence":"additional","affiliation":[{"name":"Guru Gobind Singh College of Pharmacy,\nYamunanagar, Haryana, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Geeta","family":"Deswal","sequence":"additional","affiliation":[{"name":"Guru Gobind Singh College of Pharmacy,\nYamunanagar, Haryana, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ajmer Singh","family":"Grewal","sequence":"additional","affiliation":[{"name":"Guru Gobind Singh College of Pharmacy,\nYamunanagar, Haryana, India"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"5858","DOI":"10.3390\/ijms21165858","volume":"21","author":"Uddin M.S.","year":"2020","unstructured":"Uddin M.S.; Kabir M.T.; Rahman M.S.; Behl T.; Jeandet P.; Ashraf G.M.; Najda A.; Bin-Jumah M.N.; El-Seedi H.R.; Abdel-Daim M.M.; Revisiting the amyloid cascade hypothesis: from anti-A\u03b2 therapeutics to auspicious new ways for Alzheimer\u2019s disease. Int J Mol Sci  2020,21(16),5858","journal-title":"Int J Mol Sci"},{"key":"ref=2","author":"Prince M.J.","year":"2015","unstructured":"Prince M.J.; Wimo A.; Guerchet M.M.;  World Alzheimer report 2015: the global impact of dementia: an analysis of prevalence, incidence, cost and trends; Alzheimer\u2019s Disease International  2015","journal-title":"World Alzheimer report 2015: the global impact of dementia: an analysis of prevalence, incidence, cost and trends; Alzheimer\u2019s Disease International"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1038\/nrneurol.2014.181","volume":"10","author":"Sachdev P.S.","year":"2014","unstructured":"Sachdev P.S.; Blacker D.; Blazer D.G.; Ganguli M.; Jeste D.V.; Paulsen J.S.; Petersen R.C.; Classifying neurocognitive disorders: The DSM-5 approach. Nat Rev Neurol  2014,10(11),634-642","journal-title":"Nat Rev Neurol"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"410","DOI":"10.3390\/md19080410","volume":"19","author":"Hafez Ghoran S.","year":"2021","unstructured":"Hafez Ghoran S.; Kijjoa A.; Marine-derived compounds with anti-Alzheimer\u2019s disease activities. Mar Drugs  2021,19(8),410","journal-title":"Mar Drugs"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1001\/jamaneurol.2016.4899","volume":"74","author":"Yassine H.N.","year":"2017","unstructured":"Yassine H.N.; Braskie M.N.; Mack W.J.; Castor K.J.; Fonteh A.N.; Schneider L.S.; Harrington M.G.; Chui H.C.; Association of docosahexaenoic acid supplementation with Alzheimer disease stage in apolipoprotein E \u03b54 carriers: A review. JAMA Neurol  2017,74(3),339-347","journal-title":"JAMA Neurol"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"330","DOI":"10.3945\/ajcn.115.124081","volume":"103","author":"Zhang Y.","year":"2016","unstructured":"Zhang Y.; Chen J.; Qiu J.; Li Y.; Wang J.; Jiao J.; Intakes of fish and polyunsaturated fatty acids and mild-to-severe cognitive impairment risks: A dose-response meta-analysis of 21 cohort studies. Am J Clin Nutr  2016,103(2),330-340","journal-title":"Am J Clin Nutr"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1093\/ijnp\/pyx012","volume":"20","author":"Blanco-Silvente L.","year":"2017","unstructured":"Blanco-Silvente L.; Castells X.; Saez M.; Barcel\u00f3 M.A.; Garre-Olmo J.; Vilalta-Franch J.; Capell\u00e0 D.; Discontinuation, efficacy, and safety of cholinesterase inhibitors for Alzheimer\u2019s disease: A meta-analysis and meta-regression of 43 randomized clinical trials enrolling 16 106 patients. Int J Neuropsychopharmacol  2017,20(7),519-528","journal-title":"Int J Neuropsychopharmacol"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"e0123289","DOI":"10.1371\/journal.pone.0123289","volume":"10","author":"Matsunaga S.","year":"2015","unstructured":"Matsunaga S.; Kishi T.; Iwata N.; Memantine monotherapy for Alzheimer\u2019s disease: A systematic review and meta-analysis. PLoS One  2015,10(4),e0123289","journal-title":"PLoS One"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"3267","DOI":"10.2147\/DDDT.S86463","volume":"10","author":"Deardorff W.J.","year":"2016","unstructured":"Deardorff W.J.; Grossberg G.; A fixed-dose combination of memantine extended-release and donepezil in the treatment of moderate-to-severe Alzheimer\u2019s disease. Drug Des Devel Ther  2016,10,3267-3279","journal-title":"Drug Des Devel Ther"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1007\/s12272-014-0503-5","volume":"38","author":"Choi D.Y.","year":"2015","unstructured":"Choi D.Y.; Choi H.; Natural products from marine organisms with neuroprotective activity in the experimental models of Alzheimer\u2019s disease, Parkinson\u2019s disease and ischemic brain stroke: their molecular targets and action mechanisms. Arch Pharm Res  2015,38(2),139-170","journal-title":"Arch Pharm Res"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"147","DOI":"10.15415\/jptrm.2016.42010","volume":"4","author":"Dhingra D.","year":"2016","unstructured":"Dhingra D.; Parshad S.; Improvement of learning and memory of mice by plumbagin. J Pharm Technol Res Manag  2016,4(2),147-159","journal-title":"J Pharm Technol Res Manag"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15415\/jptrm.2018.61001","volume":"6","author":"Kumar D.","year":"2018","unstructured":"Kumar D.; Kumar S.; Neuropharmacological profile of fractions of Actaea acuminata H. Hara roots. J Pharm Technol Res Manag  2018,6(1),1-8","journal-title":"J Pharm Technol Res Manag"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"251","DOI":"10.3390\/md19050251","volume":"19","author":"Kabir M.T.","year":"2021","unstructured":"Kabir M.T.; Uddin M.S.; Jeandet P.; Emran T.B.; Mitra S.; Albadrani G.M.; Sayed A.A.; Abdel-Daim M.M.; Simal-Gandara J.; Anti-Alzheimer\u2019s molecules derived from marine life: Understanding molecular mechanisms and therapeutic potential. Mar Drugs  2021,19(5),251","journal-title":"Mar Drugs"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"242","DOI":"10.3390\/ph13090242","volume":"13","author":"Martins M.","year":"2020","unstructured":"Martins M.; Silva R.; M.M. Pinto M.; Sousa E.; Marine natural products, multitarget therapy and repurposed agents in Alzheimer\u2019s disease. Pharmaceuticals  2020,13(9),242","journal-title":"Pharmaceuticals"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"5","DOI":"10.3390\/md14010005","volume":"14","author":"Russo P.","year":"2015","unstructured":"Russo P.; Kisialiou A.; Lamonaca P.; Moroni R.; Prinzi G.; Fini M.; New drugs from marine organisms in Alzheimer\u2019s disease. Mar Drugs  2015,14(1),5","journal-title":"Mar Drugs"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.2174\/0929867043364982","volume":"11","author":"Newman D.J.","year":"2004","unstructured":"Newman D.J.; Cragg G.M.; Advanced preclinical and clinical trials of natural products and related compounds from marine sources. Curr Med Chem  2004,11(13),1693-1713","journal-title":"Curr Med Chem"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.3390\/md12021066","volume":"12","author":"Martins A.","year":"2014","unstructured":"Martins A.; Vieira H.; Gaspar H.; Santos S.; Marketed marine natural products in the pharmaceutical and cosmeceutical industries: tips for success. Mar Drugs  2014,12(2),1066-1101","journal-title":"Mar Drugs"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"561","DOI":"10.4062\/biomolther.2016.181","volume":"24","author":"Lindequist U.","year":"2016","unstructured":"Lindequist U.; Marine-derived pharmaceuticals - challenges and opportunities. Biomol Ther  2016,24(6),561-571","journal-title":"Biomol Ther"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"83","DOI":"10.4103\/0975-7406.171700","volume":"8","author":"Malve H.","year":"2016","unstructured":"Malve H.; Exploring the ocean for new drug developments: Marine pharmacology. J Pharm Bioallied Sci  2016,8(2),83-91","journal-title":"J Pharm Bioallied Sci"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"201","DOI":"10.3390\/md19040201","volume":"19","author":"Bahbah E.I.","year":"2021","unstructured":"Bahbah E.I.; Ghozy S.; Attia M.S.; Negida A.; Emran T.B.; Mitra S.; Albadrani G.M.; Abdel-Daim M.M.; Uddin M.S.; Simal-Gandara J.; Molecular mechanisms of astaxanthin as a potential neurotherapeutic agent. Mar Drugs  2021,19(4),201","journal-title":"Mar Drugs"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1007\/s42995-019-00021-2","volume":"1","author":"Liu L.","year":"2019","unstructured":"Liu L.; Zheng Y.Y.; Shao C.L.; Wang C.Y.; Metabolites from marine invertebrates and their symbiotic microorganisms: Molecular diversity discovery, mining, and application. Mar Life Sci Technol  2019,1(1),60-94","journal-title":"Mar Life Sci Technol"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2017\/5245021","volume":"2017","author":"Nii-Trebi N.I.","year":"2017","unstructured":"Nii-Trebi N.I.; Emerging and neglected infectious diseases: Insights, advances, and challenges. BioMed Res Int  2017,2017,1-15","journal-title":"BioMed Res Int"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/978-3-030-20389-4_8","author":"Petersen L.E.","year":"2020","unstructured":"Petersen L.E.; Kellermann M.Y.; Schupp P.J.; Secondary metabolites of marine microbes: From natural products chemistry to chemical ecology. YOUMARES 9-The Oceans: Our Research, Our Future  2020,159-180","journal-title":"YOUMARES 9-The Oceans: Our Research, Our Future"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"246","DOI":"10.3390\/md19050246","volume":"19","author":"Varijakzhan D.","year":"2021","unstructured":"Varijakzhan D.; Loh J.Y.; Yap W.S.; Yusoff K.; Seboussi R.; Lim S.H.E.; Lai K.S.; Chong C.M.; Bioactive compounds from marine sponges: Fundamentals and applications. Mar Drugs  2021,19(5),246","journal-title":"Mar Drugs"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"123136","DOI":"10.1016\/j.ijbiomac.2023.123136","volume":"230","author":"Ghattavi S.","year":"2023","unstructured":"Ghattavi S.; Homaei A.; Marine enzymes: Classification and application in various industries. Int J Biol Macromol  2023,230,123136","journal-title":"Int J Biol Macromol"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"436","DOI":"10.3390\/jof7060436","volume":"7","author":"Noman E.","year":"2021","unstructured":"Noman E.; Al-Shaibani M.M.; Bakhrebah M.A.; Almoheer R.; Al-Sahari M.; Al-Gheethi A.; Radin Mohamed R.M.S.; Almulaiky Y.Q.; Abdulaal W.H.; Potential of anti-cancer activity of secondary metabolic products from marine fungi. J Fungi  2021,7(6),436","journal-title":"J Fungi"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"108097","DOI":"10.1016\/j.biotechadv.2023.108097","volume":"63","author":"Mrudulakumari Vasudevan U.","year":"2023","unstructured":"Mrudulakumari Vasudevan U.; Mai D.H.A.; Krishna S.; Lee E.Y.; Methanotrophs as a reservoir for bioactive secondary metabolites: Pitfalls, insights and promises. Biotechnol Adv  2023,63,108097","journal-title":"Biotechnol Adv"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"13","DOI":"10.4103\/0972-2327.40220","volume":"11","author":"Mishra S.","year":"2008","unstructured":"Mishra S.; Palanivelu K.; The effect of curcumin (turmeric) on Alzheimer\u2032s disease: An overview. Ann Indian Acad Neurol  2008,11(1),13-19","journal-title":"Ann Indian Acad Neurol"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"5541","DOI":"10.2147\/IJN.S200490","volume":"14","author":"Tiwari S.","year":"2019","unstructured":"Tiwari S.; Atluri V.; Kaushik A.; Yndart A.; Nair M.; Alzheimer\u2019s disease: Pathogenesis, diagnostics, and therapeutics. Int J Nanomedicine  2019,14,5541-5554","journal-title":"Int J Nanomedicine"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1007\/s43440-023-00481-5","volume":"75","author":"Montero-Cosme T.G.","year":"2023","unstructured":"Montero-Cosme T.G.; Pascual-Mathey L.I.; Hern\u00e1ndez-Aguilar M.E.; Herrera-Covarrubias D.; Rojas-Dur\u00e1n F.; Aranda-Abreu G.E.; Potential drugs for the treatment of Alzheimer\u2019s disease. Pharmacol Rep  2023,75(3),544-559","journal-title":"Pharmacol Rep"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1016\/j.neurobiolaging.2006.06.003","volume":"28","author":"Kalinin S.","year":"2007","unstructured":"Kalinin S.; Gavrilyuk V.; Polak P.E.; Vasser R.; Zhao J.; Heneka M.T.; Feinstein D.L.; Noradrenaline deficiency in brain increases \u03b2-amyloid plaque burden in an animal model of Alzheimer\u2019s disease. Neurobiol Aging  2007,28(8),1206-1214","journal-title":"Neurobiol Aging"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1159\/000084553","volume":"19","author":"Tomimoto H.","year":"2005","unstructured":"Tomimoto H.; Ohtani R.; Shibata M.; Nakamura N.; Ihara M.; Loss of cholinergic pathways in vascular dementia of the Binswanger type. Dement Geriatr Cogn Disord  2005,19(5-6),282-288","journal-title":"Dement Geriatr Cogn Disord"},{"key":"ref=33","first-page":"30","volume":"7","author":"Ahmed M.Q.","year":"2018","unstructured":"Ahmed M.Q.; Alenazi F.S.H.; Fazaludeen M.F.; Shahid S.M.A.; Kausar M.A.; Pathology and management of Alzheimer\u2019s disease: a review. Int J Pharm Res Allied Sci  2018,7(2),30-42","journal-title":"Int J Pharm Res Allied Sci"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"1910","DOI":"10.3390\/biomedicines9121910","volume":"9","author":"Garc\u00eda-Morales V.","year":"2021","unstructured":"Garc\u00eda-Morales V.; Gonz\u00e1lez-Acedo A.; Melguizo-Rodr\u00edguez L.; Pardo-Moreno T.; Costela-Ruiz V.J.; Montiel-Troya M.; Ramos-Rodr\u00edguez J.J.; Current understanding of the physiopathology, diagnosis and therapeutic approach to Alzheimer\u2019s disease. Biomedicines  2021,9(12),1910","journal-title":"Biomedicines"},{"key":"ref=35","first-page":"197","volume":"3","author":"Kelleher R.J.","year":"2013","unstructured":"Kelleher R.J.; Soiza R.L.; Evidence of endothelial dysfunction in the development of Alzheimer\u2019s disease: Is Alzheimer\u2019s a vascular disorder? Am J Cardiovasc Dis  2013,3(4),197-226","journal-title":"Am J Cardiovasc Dis"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.3390\/pharmaceutics15041133","volume":"15","author":"Chen H.","year":"2023","unstructured":"Chen H.; Xu J.; Xu H.; Luo T.; Li Y.; Jiang K.; Shentu Y.; Tong Z.; New insights into Alzheimer\u2019s disease: Novel pathogenesis, drug target and delivery. Pharmaceutics  2023,15(4),1133","journal-title":"Pharmaceutics"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1006\/mcne.2001.1027","volume":"18","author":"Marvanov\u00e1 M.","year":"2001","unstructured":"Marvanov\u00e1 M.; Lakso M.; Pirhonen J.; Nawa H.; Wong G.; Castr\u00e9n E.; The neuroprotective agent memantine induces brain-derived neurotrophic factor and trkB receptor expression in rat brain. Mol Cell Neurosci  2001,18(3),247-258","journal-title":"Mol Cell Neurosci"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.4103\/1673-5374.358619","volume":"18","author":"Castelli V.","year":"2023","unstructured":"Castelli V.; Alfonsetti M.; d\u2019Angelo M.; Neurotrophic factor-based pharmacological approaches in neurological disorders. Neural Regen Res  2023,18(6),1220-1228","journal-title":"Neural Regen Res"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.ejphar.2017.09.043","volume":"815","author":"Anand A.","year":"2017","unstructured":"Anand A.; Patience A.A.; Sharma N.; Khurana N.; The present and future of pharmacotherapy of Alzheimer\u2019s disease: A comprehensive review. Eur J Pharmacol  2017,815,364-375","journal-title":"Eur J Pharmacol"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.3390\/biom12101344","volume":"12","author":"Picone P.","year":"2022","unstructured":"Picone P.; Sanfilippo T.; Vasto S.; Baldassano S.; Guggino R.; Nuzzo D.; Bulone D.; San Biagio P.L.; Muscolino E.; Monastero R.; Dispenza C.; Giacomazza D.; From small peptides to large proteins against alzheimer\u2019s disease. Biomolecules  2022,12(10),1344","journal-title":"Biomolecules"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s40035-017-0093-5","volume":"6","author":"Das B.","year":"2017","unstructured":"Das B.; Yan R.; Role of BACE1 in Alzheimer\u2019s synaptic function. Transl Neurodegener  2017,6(1),23","journal-title":"Transl Neurodegener"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"178","DOI":"10.3389\/fchem.2018.00178","volume":"6","author":"Coimbra J.R.M.","year":"2018","unstructured":"Coimbra J.R.M.; Marques D.F.F.; Baptista S.J.; Pereira C.M.F.; Moreira P.I.; Dinis T.C.P.; Santos A.E.; Salvador J.A.R.; Highlights in BACE1 inhibitors for Alzheimer\u2019s disease treatment. Front Chem  2018,6,178","journal-title":"Front Chem"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1016\/j.biopsych.2020.02.001","volume":"89","author":"Hampel H.","year":"2021","unstructured":"Hampel H.; Vassar R.; De Strooper B.; Hardy J.; Willem M.; Singh N.; Zhou J.; Yan R.; Vanmechelen E.; De Vos A.; Nistic\u00f2 R.; Corbo M.; Imbimbo B.P.; Streffer J.; Voytyuk I.; Timmers M.; Tahami Monfared A.A.; Irizarry M.; Albala B.; Koyama A.; Watanabe N.; Kimura T.; Yarenis L.; Lista S.; Kramer L.; Vergallo A.; The secretase BACE1 in Alzheimer\u2019s disease. Biol Psychiatry  2021,89(8),745-756","journal-title":"Biol Psychiatry"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s13195-014-0089-7","volume":"6","author":"Vassar R.","year":"2014","unstructured":"Vassar R.; BACE1 inhibitor drugs in clinical trials for Alzheimer\u2019s disease. Alzheimers Res Ther  2014,6(9),89","journal-title":"Alzheimers Res Ther"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"6665","DOI":"10.1016\/j.bmc.2013.08.016","volume":"21","author":"Suzuki K.","year":"2013","unstructured":"Suzuki K.; Hamada Y.; Nguyen J.T.; Kiso Y.; Novel BACE1 inhibitors with a non-acidic heterocycle at the P\u2032 position. Bioorg Med Chem  2013,21(21),6665-6673","journal-title":"Bioorg Med Chem"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1186\/s12906-015-0906-y","volume":"15","author":"Liu M.","year":"2015","unstructured":"Liu M.; Guo H.; Li C.; Wang D.; Wu J.; Wang C.; Xu J.; Qin R.; Cognitive improvement of compound danshen in an A\u03b225-35 peptide-induced rat model of Alzheimer\u2019s disease. BMC Complement Altern Med  2015,15(1),382","journal-title":"BMC Complement Altern Med"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1126\/science.1072994","volume":"297","author":"Hardy J.","year":"2002","unstructured":"Hardy J.; Selkoe D.J.; The amyloid hypothesis of Alzheimer\u2019s disease: Progress and problems on the road to therapeutics. Science  2002,297(5580),353-356","journal-title":"Science"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"255","DOI":"10.3390\/bios11080255","volume":"11","author":"Luo Z.","year":"2021","unstructured":"Luo Z.; Xu H.; Liu L.; Ohulchanskyy T.Y.; Qu J.; Optical imaging of beta-amyloid plaques in Alzheimer\u2019s disease. Biosensors  2021,11(8),255","journal-title":"Biosensors"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1080\/02652048.2020.1756971","volume":"37","author":"Kaur A.","year":"2020","unstructured":"Kaur A.; Nigam K.; Srivastava S.; Tyagi A.; Dang S.; Memantine nanoemulsion: A new approach to treat Alzheimer\u2019s disease. J Microencapsul  2020,37(5),355-365","journal-title":"J Microencapsul"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1038\/s41392-019-0063-8","volume":"4","author":"Liu P.P.","year":"2019","unstructured":"Liu P.P.; Xie Y.; Meng X.Y.; Kang J.S.; History and progress of hypotheses and clinical trials for Alzheimer\u2019s disease. Signal Transduct Target Ther  2019,4(1),29","journal-title":"Signal Transduct Target Ther"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"3394","DOI":"10.3390\/molecules25153394","volume":"25","author":"Silva J.H.C.","year":"2020","unstructured":"Silva J.H.C.; Ferreira R.S.; Pereira E.P.; Braga-de-Souza S.; Almeida M.M.A.; Santos C.C.; Butt A.M.; Caiazzo E.; Capasso R.; Silva V.D.A.; Costa S.L.; Amburana cearensis: Pharmacological and neuroprotective effects of its compounds. Molecules  2020,25(15),3394","journal-title":"Molecules"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"17","DOI":"10.15415\/jmrh.2015.21002","volume":"2","author":"Long I.","year":"2015","unstructured":"Long I.; Rashid N.A.; The potential role of nicotine in the treatment of learning and memory impairment after REM sleep deprivation. J Multidiscip Healthc  2015,2(1),17-30","journal-title":"J Multidiscip Healthc"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.bbrc.2019.11.052","volume":"522","author":"Ismail N.","year":"2020","unstructured":"Ismail N.; Kureishy N.; Church S.J.; Scholefield M.; Unwin R.D.; Xu J.; Patassini S.; Cooper G.J.S.; Vitamin B5 (d-pantothenic acid) localizes in myelinated structures of the rat brain: Potential role for cerebral vitamin B5 stores in local myelin homeostasis. Biochem Biophys Res Commun  2020,522(1),220-225","journal-title":"Biochem Biophys Res Commun"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1016\/j.bbrc.2020.05.015","volume":"527","author":"Xu J.","year":"2020","unstructured":"Xu J.; Patassini S.; Begley P.; Church S.; Waldvogel H.J.; Faull R.L.M.; Unwin R.D.; Cooper G.J.S.; Cerebral deficiency of vitamin B5 (d-pantothenic acid; pantothenate) as a potentially-reversible cause of neurodegeneration and dementia in sporadic Alzheimer\u2019s disease. Biochem Biophys Res Commun  2020,527(3),676-681","journal-title":"Biochem Biophys Res Commun"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"484","DOI":"10.3390\/nu14030484","volume":"14","author":"Hrub\u0161a M.","year":"2022","unstructured":"Hrub\u0161a M.; Siatka T.; Nejmanov\u00e1 I.; Vopr\u0161alov\u00e1 M.; Kujovsk\u00e1 Kr\u010dmov\u00e1, L.; Matou\u0161ov\u00e1, K.; Javorsk\u00e1, L.; Mac\u00e1kov\u00e1, K.; Mercolini, L.; Remi\u00e3o, F.; M\u00e1\u0165u\u0161, M.; Mlad\u011bnka, P. Biological Properties of Vitamins of the B-Complex, Part 1: Vitamins B1, B2, B3, and B5. Nutrients  2022,14(3),484","journal-title":"Nutrients"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.3233\/JAD-170585","volume":"62","author":"Swerdlow R.H.","year":"2018","unstructured":"Swerdlow R.H.; Mitochondria and mitochondrial cascades in Alzheimer\u2019s disease. J Alzheimers Dis  2018,62(3),1403-1416","journal-title":"J Alzheimers Dis"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1186\/s12967-023-04493-w","volume":"21","author":"Bustamante-Barrientos F.A.","year":"2023","unstructured":"Bustamante-Barrientos F.A.; Luque-Campos N.; Araya M.J.; Lara-Barba E.; de Solminihac J.; Pradenas C.; Molina L.; Herrera-Luna Y.; Utreras-Mendoza Y.; Elizondo-Vega R.; Vega-Letter A.M.; Luz-Crawford P.; Mitochondrial dysfunction in neurodegenerative disorders: Potential therapeutic application of mitochondrial transfer to central nervous system-residing cells. J Transl Med  2023,21(1),613","journal-title":"J Transl Med"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1098\/rstb.2005.1764","volume":"360","author":"Tretter L.","year":"2005","unstructured":"Tretter L.; Adam-Vizi V.; Alpha-ketoglutarate dehydrogenase: A target and generator of oxidative stress. Philos Trans R Soc Lond B Biol Sci  2005,360(1464),2335-2345","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"2959","DOI":"10.1021\/bi2018909","volume":"51","author":"Glancy B.","year":"2012","unstructured":"Glancy B.; Balaban R.S.; Role of mitochondrial Ca2+ in the regulation of cellular energetics. Biochemistry  2012,51(14),2959-2973","journal-title":"Biochemistry"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"329","DOI":"10.3233\/JAD-141977","volume":"46","author":"Wojsiat J.","year":"2015","unstructured":"Wojsiat J.; Prandelli C.; Laskowska-Kaszub K.; Mart\u00edn-Requero A.; Wojda U.; Oxidative stress and aberrant cell cycle in Alzheimer\u2019s disease lymphocytes: diagnostic prospects. J Alzheimers Dis  2015,46(2),329-350","journal-title":"J Alzheimers Dis"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"11483","DOI":"10.1038\/ncomms11483","volume":"7","author":"Beck S.J.","year":"2016","unstructured":"Beck S.J.; Guo L.; Phensy A.; Tian J.; Wang L.; Tandon N.; Gauba E.; Lu L.; Pascual J.M.; Kroener S.; Du H.; Deregulation of mitochondrial F1FO-ATP synthase via OSCP in Alzheimer\u2019s disease. Nat Commun  2016,7(1),11483","journal-title":"Nat Commun"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"6448","DOI":"10.1073\/pnas.95.11.6448","volume":"95","author":"Lambert M.P.","year":"1998","unstructured":"Lambert M.P.; Barlow A.K.; Chromy B.A.; Edwards C.; Freed R.; Liosatos M.; Morgan T.E.; Rozovsky I.; Trommer B.; Viola K.L.; Wals P.; Zhang C.; Finch C.E.; Krafft G.A.; Klein W.L.; Diffusible, nonfibrillar ligands derived from A\u03b2 1\u201342 are potent central nervous system neurotoxins. Proc Natl Acad Sci USA  1998,95(11),6448-6453","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1097\/00001756-199304000-00024","volume":"4","author":"Shirazi S.K.","year":"1993","unstructured":"Shirazi S.K.; Wood J.G.; The protein tyrosine kinase, fyn, in Alzheimer\u02bcs disease pathology. Neuroreport  1993,4(4),435-437","journal-title":"Neuroreport"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"243","DOI":"10.3233\/JAD-2011-110353","volume":"27","author":"Yang K.","year":"2011","unstructured":"Yang K.; Belrose J.; Trepanier C.H.; Lei G.; Jackson M.F.; MacDonald J.F.; Fyn, a potential target for Alzheimer\u2019s disease. J Alzheimers Dis  2011,27(2),243-252","journal-title":"J Alzheimers Dis"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.biopsych.2017.06.004","volume":"83","author":"Nygaard H.B.","year":"2018","unstructured":"Nygaard H.B.; Targeting fyn kinase in Alzheimer\u2019s disease. Biol Psychiatry  2018,83(4),369-376","journal-title":"Biol Psychiatry"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.neures.2017.11.012","volume":"126","author":"Chun H.","year":"2018","unstructured":"Chun H.; Lee C.J.; Reactive astrocytes in Alzheimer\u2019s disease: A double-edged sword. Neurosci Res  2018,126,44-52","journal-title":"Neurosci Res"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"113320","DOI":"10.1016\/j.ejmech.2021.113320","volume":"216","author":"Srivastava S.","year":"2021","unstructured":"Srivastava S.; Ahmad R.; Khare S.K.; Alzheimer\u2019s disease and its treatment by different approaches: A review. Eur J Med Chem  2021,216,113320","journal-title":"Eur J Med Chem"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/j.pneurobio.2004.10.004","volume":"74","author":"Morgan C.","year":"2004","unstructured":"Morgan C.; Colombres M.; Nu\u00f1ez M.T.; Inestrosa N.C.; Structure and function of amyloid in Alzheimer\u2019s disease. Prog Neurobiol  2004,74(6),323-349","journal-title":"Prog Neurobiol"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1111\/jnc.12715","volume":"130","author":"Vassar R.","year":"2014","unstructured":"Vassar R.; Kuhn P.H.; Haass C.; Kennedy M.E.; Rajendran L.; Wong P.C.; Lichtenthaler S.F.; Function, therapeutic potential and cell biology of BACE proteases: current status and future prospects. J Neurochem  2014,130(1),4-28","journal-title":"J Neurochem"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1111\/j.1471-4159.2011.07519.x","volume":"120","author":"Zhang H.","year":"2012","unstructured":"Zhang H.; Ma Q.; Zhang Y.; Xu H.; Proteolytic processing of Alzheimer\u2019s \u03b2-amyloid precursor protein. J Neurochem  2012,120(S1),9-21","journal-title":"J Neurochem"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1002\/iub.1386","volume":"67","author":"Chen J.J.","year":"2015","unstructured":"Chen J.J.; Genereux J.C.; Wiseman R.L.; Endoplasmic reticulum quality control and systemic amyloid disease: Impacting protein stability from the inside out. IUBMB Life  2015,67(6),404-413","journal-title":"IUBMB Life"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"379","DOI":"10.7326\/0003-4819-148-5-200803040-00009","volume":"148","author":"Raina P.","year":"2008","unstructured":"Raina P.; Santaguida P.; Ismaila A.; Patterson C.; Cowan D.; Levine M.; Booker L.; Oremus M.; Effectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guideline. Ann Intern Med  2008,148(5),379-397","journal-title":"Ann Intern Med"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1111\/j.1476-5381.2012.02057.x","volume":"167","author":"Danysz W.","year":"2012","unstructured":"Danysz W.; Parsons C.G.; Alzheimer\u2019s disease, \u03b2-amyloid, glutamate, NMDA receptors and memantine \u2013 searching for the connections. Br J Pharmacol  2012,167(2),324-352","journal-title":"Br J Pharmacol"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"S141","DOI":"10.3233\/JAD-2012-129025","volume":"33","author":"Hernandez F.","year":"2012","unstructured":"Hernandez F.; Lucas J.J.; Avila J.; GSK3 and tau: two convergence points in Alzheimer\u2019s disease. J Alzheimers Dis  2012,33(S1),S141-S144","journal-title":"J Alzheimers Dis"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.3390\/ijms10031386","volume":"10","author":"Castellani R.","year":"2009","unstructured":"Castellani R.; Zhu X.; Lee H.G.; Smith M.; Perry G.; Molecular pathogenesis of Alzheimer\u2019s disease: Reductionist versus expansionist approaches. Int J Mol Sci  2009,10(3),1386-1406","journal-title":"Int J Mol Sci"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/nrneurol.2009.218","volume":"6","author":"De Strooper B.","year":"2010","unstructured":"De Strooper B.; Vassar R.; Golde T.; The secretases: enzymes with therapeutic potential in Alzheimer disease. Nat Rev Neurol  2010,6(2),99-107","journal-title":"Nat Rev Neurol"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1016\/S0896-6273(00)80108-7","volume":"16","author":"Inestrosa N.C.","year":"1996","unstructured":"Inestrosa N.C.; Alvarez A.; P\u00e9rez C.A.; Moreno R.D.; Vicente M.; Linker C.; Casanueva O.I.; Soto C.; Garrido J.; Acetylcholinesterase accelerates assembly of amyloid-beta-peptides into Alzheimer\u2019s fibrils: Possible role of the peripheral site of the enzyme. Neuron  1996,16(4),881-891","journal-title":"Neuron"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"217","DOI":"10.2174\/138161206775193127","volume":"12","author":"Johnson G.","year":"2006","unstructured":"Johnson G.; Moore S.; The peripheral anionic site of acetylcholinesterase: Structure, functions and potential role in rational drug design. Curr Pharm Des  2006,12(2),217-225","journal-title":"Curr Pharm Des"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/1750-1326-5-4","volume":"5","author":"Dinamarca M.C.","year":"2010","unstructured":"Dinamarca M.C.; Sagal J.P.; Quintanilla R.A.; Godoy J.A.; Arr\u00e1zola M.S.; Inestrosa N.C.; Amyloid-\u03b2-Acetylcholinesterase complexes potentiate neurodegenerative changes induced by the A\u03b2 peptide. Implications for the pathogenesis of Alzheimer\u2019s disease. Mol Neurodegener  2010,5(1),4","journal-title":"Mol Neurodegener"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"3213","DOI":"10.1523\/JNEUROSCI.18-09-03213.1998","volume":"18","author":"Alvarez A.","year":"1998","unstructured":"Alvarez A.; Alarc\u00f3n R.; Opazo C.; Campos E.O.; Mu\u00f1oz F.J.; Calder\u00f3n F.H.; Dajas F.; Gentry M.K.; Doctor B.P.; De Mello F.G.; Inestrosa N.C.; Stable complexes involving acetylcholinesterase and amyloid-beta peptide change the biochemical properties of the enzyme and increase the neurotoxicity of Alzheimer\u2019s fibrils. J Neurosci  1998,18(9),3213-3223","journal-title":"J Neurosci"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"138","DOI":"10.4103\/0972-2327.144284","volume":"18","author":"Taneja V.","year":"2015","unstructured":"Taneja V.; Verma M.; Vats A.; Toxic species in amyloid disorders: Oligomers or mature fibrils. Ann Indian Acad Neurol  2015,18(2),138-145","journal-title":"Ann Indian Acad Neurol"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.neuint.2008.06.005","volume":"53","author":"P\u00e1k\u00e1ski M.","year":"2008","unstructured":"P\u00e1k\u00e1ski M.; K\u00e1lm\u00e1n J.; Interactions between the amyloid and cholinergic mechanisms in Alzheimer\u2019s disease. Neurochem Int  2008,53(5),103-111","journal-title":"Neurochem Int"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/S0011-393X(03)00059-6","volume":"64","author":"Grossberg G.T.","year":"2003","unstructured":"Grossberg G.T.; Cholinesterase inhibitors for the treatment of Alzheimer\u2019s disease: getting on and staying on. Curr Ther Res Clin Exp  2003,64(4),216-235","journal-title":"Curr Ther Res Clin Exp"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"43","DOI":"10.3389\/fnins.2019.00043","volume":"13","author":"Liu J.","year":"2019","unstructured":"Liu J.; Chang L.; Song Y.; Li H.; Wu Y.; The role of NMDA receptors in Alzheimer\u2019s disease. Front Neurosci  2019,13,43","journal-title":"Front Neurosci"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"918","DOI":"10.2174\/1567205011666141107150331","volume":"11","author":"Cisek K.","year":"2014","unstructured":"Cisek K.; Cooper G.; Huseby C.; Kuret J.; Structure and mechanism of action of tau aggregation inhibitors. Curr Alzheimer Res  2014,11(10),918-927","journal-title":"Curr Alzheimer Res"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1038\/s41582-020-00435-y","volume":"17","author":"Leng F.","year":"2021","unstructured":"Leng F.; Edison P.; Neuroinflammation and microglial activation in Alzheimer disease: where do we go from here? Nat Rev Neurol  2021,17(3),157-172","journal-title":"Nat Rev Neurol"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"6846","DOI":"10.1021\/ja00388a092","volume":"104","author":"Pettit G.R.","year":"1982","unstructured":"Pettit G.R.; Herald C.L.; Doubek D.L.; Herald D.L.; Arnold E.; Clardy J.; Isolation and structure of bryostatin 1. J Am Chem Soc  1982,104(24),6846-6848","journal-title":"J Am Chem Soc"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"3490","DOI":"10.1161\/STROKEAHA.113.002411","volume":"44","author":"Tan Z.","year":"2013","unstructured":"Tan Z.; Turner R.C.; Leon R.L.; Li X.; Hongpaisan J.; Zheng W.; Logsdon A.F.; Naser Z.J.; Alkon D.L.; Rosen C.L.; Huber J.D.; Bryostatin improves survival and reduces ischemic brain injury in aged rats after acute ischemic stroke. Stroke  2013,44(12),3490-3497","journal-title":"Stroke"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"3016","DOI":"10.1021\/acs.biochem.9b00427","volume":"58","author":"Blanco F.A.","year":"2019","unstructured":"Blanco F.A.; Czikora A.; Kedei N.; You Y.; Mitchell G.A.; Pany S.; Ghosh A.; Blumberg P.M.; Das J.; Munc13 is a molecular target of bryostatin 1. Biochemistry  2019,58(27),3016-3030","journal-title":"Biochemistry"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"521","DOI":"10.3233\/JAD-170161","volume":"58","author":"Nelson T.J.","year":"2017","unstructured":"Nelson T.J.; Sun M.K.; Lim C.; Sen A.; Khan T.; Chirila F.V.; Alkon D.L.; Bryostatin effects on cognitive function and PKC\u025b in Alzheimer\u2019s disease phase IIa and expanded access trials. J Alzheimers Dis  2017,58(2),521-535","journal-title":"J Alzheimers Dis"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.nbd.2014.05.033","volume":"72","author":"Malnar M.","year":"2014","unstructured":"Malnar M.; Hecimovic S.; Mattsson N.; Zetterberg H.; Bidirectional links between Alzheimer's disease and Niemann-Pick type C disease. Neurobiol Dis  2014,72(Pt A),37-47","journal-title":"Neurobiol Dis"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1046\/j.1471-4159.1996.67010317.x","volume":"67","author":"Matsushima H.","year":"1996","unstructured":"Matsushima H.; Shimohama S.; Chachin M.; Taniguchi T.; Kimura J.; Ca2+-dependent and Ca2+-independent protein kinase C changes in the brain of patients with Alzheimer\u2019s disease. J Neurochem  1996,67(1),317-323","journal-title":"J Neurochem"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1523\/JNEUROSCI.5209-10.2011","volume":"31","author":"Hongpaisan J.","year":"2011","unstructured":"Hongpaisan J.; Sun M.K.; Alkon D.L.; PKC \u03b5 activation prevents synaptic loss, A\u03b2 elevation, and cognitive deficits in Alzheimer\u2019s disease transgenic mice. J Neurosci  2011,31(2),630-643","journal-title":"J Neurosci"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"1187411","DOI":"10.3389\/fphar.2023.1187411","volume":"14","author":"Tian Z.","year":"2023","unstructured":"Tian Z.; Lu X.T.; Jiang X.; Tian J.; Bryostatin-1: A promising compound for neurological disorders. Front Pharmacol  2023,14,1187411","journal-title":"Front Pharmacol"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1527-3458.2006.00001.x","volume":"12","author":"Sun M.K.","year":"2006","unstructured":"Sun M.K.; Alkon D.L.; Bryostatin-1: Pharmacology and therapeutic potential as a CNS drug. CNS Drug Rev  2006,12(1),1-8","journal-title":"CNS Drug Rev"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/S0145-2126(96)00123-3","volume":"21","author":"Stone R.M.","year":"1997","unstructured":"Stone R.M.; Bryostatin 1: Differentiating agent from the depths. Leuk Res  1997,21(5),399-401","journal-title":"Leuk Res"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S1381-5148(00)00038-9","volume":"46","author":"Ravi Kumar M.N.V.","year":"2000","unstructured":"Ravi Kumar M.N.V.; A review of chitin and chitosan applications. React Funct Polym  2000,46(1),1-27","journal-title":"React Funct Polym"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/S0144-8617(00)00200-9","volume":"44","author":"Jeon Y.","year":"2001","unstructured":"Jeon Y.; Park P.J.; Kim S.K.; Antimicrobial effect of chitooligosaccharides produced by bioreactor. Carbohydr Polym  2001,44(1),71-76","journal-title":"Carbohydr Polym"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.3390\/md8072117","volume":"8","author":"Pangestuti R.","year":"2010","unstructured":"Pangestuti R.; Kim S.K.; Neuroprotective properties of chitosan and its derivatives. Mar Drugs  2010,8(7),2117-2128","journal-title":"Mar Drugs"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.neulet.2008.08.040","volume":"444","author":"Zhou S.","year":"2008","unstructured":"Zhou S.; Yang Y.; Gu X.; Ding F.; Chitooligosaccharides protect cultured hippocampal neurons against glutamate-induced neurotoxicity. Neurosci Lett  2008,444(3),270-274","journal-title":"Neurosci Lett"},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.ijbiomac.2017.07.021","volume":"105","year":"2017","unstructured":"AnjiReddy K.; Karpagam, S. Chitosan nanofilm and electrospun nanofiber for quick drug release in the treatment of Alzheimer\u2019s disease: In vitro and in vivo evaluation. Int J Biol Macromol  2017,105(Pt 1),131-142","journal-title":"Int J Biol Macromol"},{"key":"ref=102","doi-asserted-by":"publisher","first-page":"140886","DOI":"10.1016\/j.cej.2022.140886","volume":"456","author":"Yang C.","year":"2023","unstructured":"Yang C.; Ding X.; Yang C.; Shang L.; Zhao Y.; Marine polymers-alginate\/chitosan composited microcapsules for wound healing. Chem Eng J  2023,456,140886","journal-title":"Chem Eng J"},{"key":"ref=103","doi-asserted-by":"publisher","first-page":"2204","DOI":"10.4103\/1673-5374.310685","volume":"16","author":"Petroianu G.A.","year":"2021","unstructured":"Petroianu G.A.; Manek E.; Chitosan-based nanoparticles in Alzheimer\u2019s disease: Messenger or message? Neural Regen Res  2021,16(11),2204-2205","journal-title":"Neural Regen Res"},{"key":"ref=104","doi-asserted-by":"publisher","first-page":"4866","DOI":"10.3390\/molecules25204866","volume":"25","author":"Manek E.","year":"2020","unstructured":"Manek E.; Darvas F.; Petroianu G.A.; Use of biodegradable, chitosan-based nanoparticles in the treatment of Alzheimer\u2019s disease. Molecules  2020,25(20),4866","journal-title":"Molecules"},{"key":"ref=105","doi-asserted-by":"publisher","first-page":"322","DOI":"10.3390\/md15110322","volume":"15","author":"Ouyang Q.Q.","year":"2017","unstructured":"Ouyang Q.Q.; Zhao S.; Li S.D.; Song C.; Application of chitosan, chitooligosaccharide, and their derivatives in the treatment of Alzheimer\u2019s disease. Mar Drugs  2017,15(11),322","journal-title":"Mar Drugs"},{"key":"ref=106","doi-asserted-by":"publisher","first-page":"111838","DOI":"10.1016\/j.colsurfb.2021.111838","volume":"205","author":"Saini S.","year":"2021","unstructured":"Saini S.; Sharma T.; Jain A.; Kaur H.; Katare O.P.; Singh B.; Systematically designed chitosan-coated solid lipid nanoparticles of ferulic acid for effective management of Alzheimer\u2019s disease: A preclinical evidence. Colloids Surf B Biointerfaces  2021,205,111838","journal-title":"Colloids Surf B Biointerfaces"},{"key":"ref=107","doi-asserted-by":"publisher","first-page":"1228679","DOI":"10.3389\/fcell.2023.1228679","volume":"11","author":"Hu L.","year":"2023","unstructured":"Hu L.; Tao Y.; Jiang Y.; Qin F.; Recent progress of nanomedicine in the treatment of Alzheimer\u2019s disease. Front Cell Dev Biol  2023,11,1228679","journal-title":"Front Cell Dev Biol"},{"key":"ref=108","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.ijbiomac.2021.02.216","volume":"179","author":"Hu Q.","year":"2021","unstructured":"Hu Q.; Luo Y.; Chitosan-based nanocarriers for encapsulation and delivery of curcumin: A review. Int J Biol Macromol  2021,179,125-135","journal-title":"Int J Biol Macromol"},{"key":"ref=109","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1016\/j.ijbiomac.2014.08.052","volume":"72","author":"Sarvaiya J.","year":"2015","unstructured":"Sarvaiya J.; Agrawal Y.K.; Chitosan as a suitable nanocarrier material for anti-Alzheimer drug delivery. Int J Biol Macromol  2015,72,454-465","journal-title":"Int J Biol Macromol"},{"key":"ref=110","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1038\/nature05292","volume":"443","author":"Lin M.T.","year":"2006","unstructured":"Lin M.T.; Beal M.F.; Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature  2006,443(7113),787-795","journal-title":"Nature"},{"key":"ref=111","doi-asserted-by":"publisher","first-page":"1093038","DOI":"10.3389\/fphar.2023.1093038","volume":"14","author":"Chen Q.","year":"2023","unstructured":"Chen Q.; Ruan D.; Shi J.; Du D.; Bian C.; The multifaceted roles of natural products in mitochondrial dysfunction. Front Pharmacol  2023,14,1093038","journal-title":"Front Pharmacol"},{"key":"ref=112","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1021\/cn4001878","volume":"5","author":"Leir\u00f3s M.","year":"2014","unstructured":"Leir\u00f3s M.; Alonso E.; Sanchez J.A.; Rateb M.E.; Ebel R.; Houssen W.E.; Jaspars M.; Alfonso A.; Botana L.M.; Mitigation of ROS insults by Streptomyces secondary metabolites in primary cortical neurons. ACS Chem Neurosci  2014,5(1),71-80","journal-title":"ACS Chem Neurosci"},{"key":"ref=113","doi-asserted-by":"publisher","first-page":"107749","DOI":"10.1016\/j.pharmthera.2020.107749","volume":"221","author":"Liang Z.","year":"2021","unstructured":"Liang Z.; Currais A.; Soriano-Castell D.; Schubert D.; Maher P.; Natural products targeting mitochondria: Emerging therapeutics for age-associated neurological disorders. Pharmacol Ther  2021,221,107749","journal-title":"Pharmacol Ther"},{"key":"ref=114","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1007\/BF02977899","volume":"28","author":"Liu R.","year":"2005","unstructured":"Liu R.; Cui C.B.; Duan L.; Gu Q.Q.; Zhu W.M.; Potentin Vitro anticancer activity of metacycloprodigiosin and undecylprodigiosin from a sponge-derived actinomyceteSac-charopolyspora sp. nov. Arch Pharm Res  2005,28(12),1341-1344","journal-title":"Arch Pharm Res"},{"key":"ref=115","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.neuroscience.2015.07.082","volume":"305","author":"Leir\u00f3s M.","year":"2015","unstructured":"Leir\u00f3s M.; Alonso E.; Rateb M.E.; Ebel R.; Jaspars M.; Alfonso A.; Botana L.M.; The Streptomyces metabolite anhydroexfoliamycin ameliorates hallmarks of Alzheimer\u2019s disease in vitro and in vivo. Neuroscience  2015,305,26-35","journal-title":"Neuroscience"},{"key":"ref=116","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1021\/ml400233e","volume":"4","author":"Brunden K.R.","year":"2013","unstructured":"Brunden K.R.; Gardner N.M.; James M.J.; Yao Y.; Trojanowski J.Q.; Lee V.M.Y.; Paterson I.; Ballatore C.; Smith A.B.; III MT-stabilizer, dictyostatin, exhibits prolonged brain retention and activity: potential therapeutic implications. ACS Med Chem Lett  2013,4(9),886-889","journal-title":"ACS Med Chem Lett"},{"key":"ref=117","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1186\/s40478-016-0378-4","volume":"4","author":"Makani V.","year":"2016","unstructured":"Makani V.; Zhang B.; Han H.; Yao Y.; Lassalas P.; Lou K.; Paterson I.; Lee V.M.Y.; Trojanowski J.Q.; Ballatore C.; Smith A.B.; Brunden K.R.; Evaluation of the brain-penetrant microtubule-stabilizing agent, dictyostatin, in the PS19 tau transgenic mouse model of tauopathy. Acta Neuropathol Commun  2016,4(1),106","journal-title":"Acta Neuropathol Commun"},{"key":"ref=118","doi-asserted-by":"publisher","first-page":"6534","DOI":"10.1016\/j.tet.2010.01.083","volume":"66","author":"Paterson I.","year":"2010","unstructured":"Paterson I.; Britton R.; Delgado O.; Gardner N.M.; Meyer A.; Naylor G.J.; Poullennec K.G.; Total synthesis of (\u2212)-dictyostatin, a microtubule-stabilising anticancer macrolide of marine sponge origin. Tetrahedron  2010,66(33),6534-6545","journal-title":"Tetrahedron"},{"key":"ref=119","doi-asserted-by":"publisher","first-page":"25","DOI":"10.3389\/fnins.2018.00025","volume":"12","author":"Kametani F.","year":"2018","unstructured":"Kametani F.; Hasegawa M.; Reconsideration of amyloid hypothesis and tau hypothesis in Alzheimer\u2019s disease. Front Neurosci  2018,12,25","journal-title":"Front Neurosci"},{"key":"ref=120","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1039\/C0NP00027B","volume":"28","author":"Williams P.","year":"2011","unstructured":"Williams P.; Sorribas A.; Howes M.J.R.; Natural products as a source of Alzheimer\u2019s drug leads. Nat Prod Rep  2011,28(1),48-77","journal-title":"Nat Prod Rep"},{"key":"ref=121","doi-asserted-by":"publisher","first-page":"49","DOI":"10.3390\/md19020049","volume":"19","author":"Mayer A.M.S.","year":"2021","unstructured":"Mayer A.M.S.; Guerrero A.J.; Rodr\u00edguez A.D.; Taglialatela-Scafati O.; Nakamura F.; Fusetani N.; Marine pharmacology in 2016-2017: Marine compounds with antibacterial, antidiabetic, antifungal, anti-inflammatory, antiprotozoal, antituberculosis and antiviral activities; affecting the immune and nervous systems, and other miscellaneous mechanisms of action. Mar Drugs  2021,19(2),49","journal-title":"Mar Drugs"},{"key":"ref=122","first-page":"CD001747","author":"Olin J.","year":"2002","unstructured":"Olin J.; Schneider L.; Galantamine for Alzheimer\u2019s disease. Cochrane Database Syst Rev  2002(3),CD001747","journal-title":"Cochrane Database Syst Rev"},{"key":"ref=123","doi-asserted-by":"crossref","first-page":"537","DOI":"10.2741\/e840","volume":"10","author":"Lakshmi S.","year":"2018","unstructured":"Lakshmi S.; Prakash P.; Essa M.M.; Qoronfleh W.M.; Akbar M.; Song B.J.; Kumar S.; Elumalai P.; Marine derived bioactive compounds for treatment of Alzheimer\u2019s disease. Front Biosci  2018,10(3),537-548","journal-title":"Front Biosci"},{"key":"ref=124","first-page":"391","volume":"10","author":"Hager K.","year":"2014","unstructured":"Hager K.; Baseman A.S.; Nye J.S.; Brashear H.R.; Han J.; Sano M.; Davis B.; Richards H.M.; Effects of galantamine in a 2-year, randomized, placebo-controlled study in Alzheimer\u2019s disease. Neuropsychiatr Dis Treat  2014,10,391-401","journal-title":"Neuropsychiatr Dis Treat"},{"key":"ref=125","doi-asserted-by":"publisher","first-page":"210","DOI":"10.2174\/156720510791050812","volume":"7","author":"Williams P.","year":"2010","unstructured":"Williams P.; Sorribas A.; Liang Z.; New methods to explore marine resources for Alzheimer\u2019s therapeutics. Curr Alzheimer Res  2010,7(3),210-213","journal-title":"Curr Alzheimer Res"},{"key":"ref=126","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1039\/b508966m","volume":"23","author":"Houghton P.J.","year":"2006","unstructured":"Houghton P.J.; Ren Y.; Howes M.J.; Acetylcholinesterase inhibitors from plants and fungi. Nat Prod Rep  2006,23(2),181-199","journal-title":"Nat Prod Rep"},{"key":"ref=127","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1159\/000051227","volume":"11","author":"Maelicke A.","year":"2000","unstructured":"Maelicke A.; Allosteric modulation of nicotinic receptors as a treatment strategy for Alzheimer\u2019s disease. Dement Geriatr Cogn Disord  2000,11(1),11-18","journal-title":"Dement Geriatr Cogn Disord"},{"key":"ref=128","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/bs.alkal.2020.03.001","volume":"84","author":"Kubota T.","year":"2020","unstructured":"Kubota T.; Kurimoto S.I.; Kobayashi J.; The manzamine alkaloids. The Alkaloids; Chemistry and Biology  2020,84,1-124","journal-title":"The Alkaloids; Chemistry and Biology"},{"key":"ref=129","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1021\/np060092r","volume":"70","author":"Hamann M.","year":"2007","unstructured":"Hamann M.; Alonso D.; Mart\u00edn-Aparicio E.; Fuertes A.; P\u00e9rez-Puerto M.J.; Castro A.; Morales S.; Navarro M.L.; del Monte-Mill\u00e1n M.; Medina M.; Pennaka H.; Balaiah A.; Peng J.; Cook J.; Wahyuono S.; Mart\u00ednez A.; Glycogen synthase kinase-3 (GSK-3) inhibitory activity and structure-activity relationship (SAR) studies of the manzamine alkaloids. Potential for Alzheimer\u2019s disease. J Nat Prod  2007,70(9),1397-1405","journal-title":"J Nat Prod"},{"key":"ref=130","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1242\/jcs.00384","volume":"116","author":"Doble B.W.","year":"2003","unstructured":"Doble B.W.; Woodgett J.R.; GSK-3: tricks of the trade for a multi-tasking kinase. J Cell Sci  2003,116(7),1175-1186","journal-title":"J Cell Sci"},{"key":"ref=131","doi-asserted-by":"publisher","first-page":"32","DOI":"10.3389\/fnmol.2011.00032","volume":"4","author":"Eldar-Finkelman H.","year":"2011","unstructured":"Eldar-Finkelman H.; Martinez A.; GSK-3 inhibitors: Preclinical and clinical focus on CNS. Front Mol Neurosci  2011,4,32","journal-title":"Front Mol Neurosci"},{"key":"ref=132","doi-asserted-by":"publisher","first-page":"2043","DOI":"10.3892\/mmr.2014.2080","volume":"9","author":"Li D.W.","year":"2014","unstructured":"Li D.W.; Liu Z.Q.; Wei-Chen; Min-Yao; Li, G.R. Association of glycogen synthase kinase-3\u03b2 with Parkinson\u2019s disease (Review). Mol Med Rep  2014,9(6),2043-2050","journal-title":"Mol Med Rep"},{"key":"ref=133","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.neuropharm.2015.02.015","volume":"93","author":"Leir\u00f3s M.","year":"2015","unstructured":"Leir\u00f3s M.; Alonso E.; Rateb M.E.; Houssen W.E.; Ebel R.; Jaspars M.; Alfonso A.; Botana L.M.; Gracilins: Spongionella-derived promising compounds for Alzheimer disease. Neuropharmacology  2015,93,285-293","journal-title":"Neuropharmacology"},{"key":"ref=134","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s10571-019-00758-5","volume":"40","author":"Gegunde S.","year":"2020","unstructured":"Gegunde S.; Alfonso A.; Alonso E.; Alvari\u00f1o R.; Botana L.M.; Gracilin-derivatives as lead compounds for anti-inflammatory effects. Cell Mol Neurobiol  2020,40(4),603-615","journal-title":"Cell Mol Neurobiol"},{"key":"ref=135","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1021\/np900233c","volume":"72","author":"Rateb M.E.","year":"2009","unstructured":"Rateb M.E.; Houssen W.E.; Schumacher M.; Harrison W.T.A.; Diederich M.; Ebel R.; Jaspars M.; Bioactive diterpene derivatives from the marine sponge Spongionella sp. J Nat Prod  2009,72(8),1471-1476","journal-title":"J Nat Prod"},{"key":"ref=136","doi-asserted-by":"publisher","first-page":"100","DOI":"10.3390\/md21020100","volume":"21","author":"Gago F.","year":"2023","unstructured":"Gago F.; Computational approaches to enzyme inhibition by marine natural products in the search for new drugs. Mar Drugs  2023,21(2),100","journal-title":"Mar Drugs"},{"key":"ref=137","first-page":"256","volume":"45","author":"Nirmal N.","year":"2008","unstructured":"Nirmal N.; Praba G.O.; Velmurugan D.; Modeling studies on phospholipase A2-inhibitor complexes. Indian J Biochem Biophys  2008,45(4),256-262","journal-title":"Indian J Biochem Biophys"},{"key":"ref=138","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1194\/jlr.R300016-JLR200","volume":"45","author":"Sun G.Y.","year":"2004","unstructured":"Sun G.Y.; Xu J.; Jensen M.D.; Simonyi A.; Phospholipase A2 in the central nervous system. J Lipid Res  2004,45(2),205-213","journal-title":"J Lipid Res"},{"key":"ref=139","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1111\/j.1444-2906.2007.01511.x","volume":"74","author":"Yoon N.Y.","year":"2008","unstructured":"Yoon N.Y.; Chung H.Y.; Kim H.R.; Choi J.S.; Acetyl- and butyrylcholinesterase inhibitory activities of sterols and phlorotannins from Ecklonia stolonifera. Fish Sci  2008,74(1),200-207","journal-title":"Fish Sci"},{"key":"ref=140","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1016\/j.jff.2013.08.010","volume":"5","author":"Sugiura Y.","year":"2013","unstructured":"Sugiura Y.; Tanaka R.; Katsuzaki H.; Imai K.; Matsushita T.; The anti-inflammatory effects of phlorotannins from Eisenia arborea on mouse ear edema by inflammatory inducers. J Funct Foods  2013,5(4),2019-2023","journal-title":"J Funct Foods"},{"key":"ref=141","doi-asserted-by":"publisher","first-page":"359","DOI":"10.4014\/jmb.1910.10068","volume":"30","author":"Nho J.A.","year":"2020","unstructured":"Nho J.A.; Shin Y.S.; Jeong H.R.; Cho S.; Heo H.J.; Kim G.H.; Kim D.O.; Neuroprotective effects of phlorotannin-rich extract from brown seaweed Ecklonia cava on neuronal PC-12 and SH-SY5Y cells with oxidative stress. J Microbiol Biotechnol  2020,30(3),359-367","journal-title":"J Microbiol Biotechnol"},{"key":"ref=142","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.etap.2012.03.006","volume":"34","author":"Kang S.M.","year":"2012","unstructured":"Kang S.M.; Cha S.H.; Ko J.Y.; Kang M.C.; Kim D.; Heo S.J.; Kim J.S.; Heu M.S.; Kim Y.T.; Jung W.K.; Jeon Y.J.; Neuroprotective effects of phlorotannins isolated from a brown alga, Ecklonia cava, against H2O2-induced oxidative stress in murine hippocampal HT22 cells. Environ Toxicol Pharmacol  2012,34(1),96-105","journal-title":"Environ Toxicol Pharmacol"},{"key":"ref=143","doi-asserted-by":"publisher","first-page":"7099","DOI":"10.1523\/JNEUROSCI.21-18-07099.2001","volume":"21","author":"Cowan C.M.","year":"2001","unstructured":"Cowan C.M.; Thai J.; Krajewski S.; Reed J.C.; Nicholson D.W.; Kaufmann S.H.; Roskams A.J.; Caspases 3 and 9 send a pro-apoptotic signal from synapse to cell body in olfactory receptor neurons. J Neurosci  2001,21(18),7099-7109","journal-title":"J Neurosci"},{"key":"ref=144","doi-asserted-by":"publisher","first-page":"1982","DOI":"10.1096\/fj.02-0327fje","volume":"16","author":"Garrido J.L.","year":"2002","unstructured":"Garrido J.L.; Godoy J.; Alvarez A.; Bronfman M.; Inestrosa N.C.; Protein kinase C inhibits amyloid \u03b2\u2010peptide neurotoxicity by acting on members of the Wnt pathway. FASEB J  2002,16(14),1982-1984","journal-title":"FASEB J"},{"key":"ref=145","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.ejphar.2009.06.015","volume":"617","author":"Luo D.","year":"2009","unstructured":"Luo D.; Zhang Q.; Wang H.; Cui Y.; Sun Z.; Yang J.; Zheng Y.; Jia J.; Yu F.; Wang X.; Wang X.; Fucoidan protects against dopaminergic neuron death in vivo and in vitro. Eur J Pharmacol  2009,617(1-3),33-40","journal-title":"Eur J Pharmacol"},{"key":"ref=146","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1016\/j.carbpol.2009.10.040","volume":"79","author":"Eftekharzadeh B.","year":"2010","unstructured":"Eftekharzadeh B.; Khodagholi F.; Abdi A.; Maghsoudi N.; Alginate protects NT2 neurons against H2O2-induced neurotoxicity. Carbohydr Polym  2010,79(4),1063-1072","journal-title":"Carbohydr Polym"},{"key":"ref=147","doi-asserted-by":"publisher","first-page":"74","DOI":"10.3746\/jfn.2007.12.2.074","volume":"12","author":"Lee H.R.","year":"2007","unstructured":"Lee H.R.; Do H.; Lee S.R.; Sohn E.S.; Pyo S.N.; Son E.W.; Effects of fucoidan on neuronal cell proliferation-association with NO production through the iNOS pathway. Prev Nutr Food Sci  2007,12(2),74-78","journal-title":"Prev Nutr Food Sci"},{"key":"ref=148","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1007\/s10571-011-9792-0","volume":"32","author":"Gao Y.","year":"2012","unstructured":"Gao Y.; Dong C.; Yin J.; Shen J.; Tian J.; Li C.; Neuroprotective effect of fucoidan on H2O2-induced apoptosis in PC12 cells via activation of PI3K\/Akt pathway. Cell Mol Neurobiol  2012,32(4),523-529","journal-title":"Cell Mol Neurobiol"},{"key":"ref=149","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.neulet.2003.09.013","volume":"353","author":"Uhm C.S.","year":"2003","unstructured":"Uhm C.S.; Kim K.B.; Lim J.H.; Pee D.H.; Kim Y.H.; Kim H.; Eun B.L.; Tockgo Y.C.; Effective treatment with fucoidin for perinatal hypoxic\u2013ischemic encephalopathy in rats. Neurosci Lett  2003,353(1),21-24","journal-title":"Neurosci Lett"},{"key":"ref=150","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1016\/j.biopha.2018.11.015","volume":"109","author":"Kim H.","year":"2019","unstructured":"Kim H.; Ahn J.H.; Song M.; Kim D.W.; Lee T.K.; Lee J.C.; Kim Y.M.; Kim J.D.; Cho J.H.; Hwang I.K.; Yan B.C.; Won M.H.; Park J.H.; Pretreated fucoidan confers neuroprotection against transient global cerebral ischemic injury in the gerbil hippocampal CA1 area via reducing of glial cell activation and oxidative stress. Biomed Pharmacother  2019,109,1718-1727","journal-title":"Biomed Pharmacother"},{"key":"ref=151","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1038\/nrn1100","volume":"4","author":"Vila M.","year":"2003","unstructured":"Vila M.; Przedborski S.; Targeting programmed cell death in neurodegenerative diseases. Nat Rev Neurosci  2003,4(5),365-375","journal-title":"Nat Rev Neurosci"},{"key":"ref=152","doi-asserted-by":"publisher","first-page":"C790","DOI":"10.1152\/ajpcell.00425.2003","volume":"287","author":"Akimoto T.","year":"2004","unstructured":"Akimoto T.; Sorg B.S.; Yan Z.; Real-time imaging of peroxisome proliferator-activated receptor-\u03b3 coactivator-1\u03b1 promoter activity in skeletal muscles of living mice. Am J Physiol Cell Physiol  2004,287(3),C790-C796","journal-title":"Am J Physiol Cell Physiol"},{"key":"ref=153","doi-asserted-by":"publisher","first-page":"2118","DOI":"10.1128\/AEM.72.3.2118-2125.2006","volume":"72","author":"Kim T.K.","year":"2006","unstructured":"Kim T.K.; Hewavitharana A.K.; Shaw P.N.; Fuerst J.A.; Discovery of a new source of rifamycin antibiotics in marine sponge actinobacteria by phylogenetic prediction. Appl Environ Microbiol  2006,72(3),2118-2125","journal-title":"Appl Environ Microbiol"},{"key":"ref=154","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s00401-004-0867-6","volume":"108","author":"Kilic U.","year":"2004","unstructured":"Kilic U.; Kilic E.; Lingor P.; Yulug B.; B\u00e4hr M.; Rifampicin inhibits neurodegeneration in the optic nerve transection model in vivo and after 1-methyl-4-phenylpyridinium intoxication in vitro. Acta Neuropathol  2004,108(1),65-68","journal-title":"Acta Neuropathol"},{"key":"ref=155","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/0014-5793(93)81399-K","volume":"324","author":"Dyrks T.","year":"1993","unstructured":"Dyrks T.; Dyrks E.; Masters C.L.; Beyreuther K.; Amyloidogenicity of rodent and human beta A4 sequences. FEBS Lett  1993,324(2),231-236","journal-title":"FEBS Lett"},{"key":"ref=156","doi-asserted-by":"publisher","first-page":"3270","DOI":"10.1073\/pnas.91.8.3270","volume":"91","author":"Hensley K.","year":"1994","unstructured":"Hensley K.; Carney J.M.; Mattson M.P.; Aksenova M.; Harris M.; Wu J.F.; Floyd R.A.; Butterfield D.A.; A model for beta-amyloid aggregation and neurotoxicity based on free radical generation by the peptide: Relevance to Alzheimer disease. Proc Natl Acad Sci USA  1994,91(8),3270-3274","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=157","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1006\/bbrc.1994.2428","volume":"204","author":"Tomiyama T.","year":"1994","unstructured":"Tomiyama T.; Asano S.; Suwa Y.; Morita T.; Kataoka K.; Mori H.; Endo N.; Rifampicin prevents the aggregation and neurotoxicity of amyloid beta protein in vitro. Biochem Biophys Res Commun  1994,204(1),76-83","journal-title":"Biochem Biophys Res Commun"},{"key":"ref=158","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1093\/jac\/31.5.731","volume":"31","author":"Mindermann T.","year":"1993","unstructured":"Mindermann T.; Landolt H.; Zimmerli W.; Rajacic Z.; Gratzl O.; Penetration of rifampicin into the brain tissue and cerebral extracellular space of rats. J Antimicrob Chemother  1993,31(5),731-737","journal-title":"J Antimicrob Chemother"},{"key":"ref=159","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1042\/bj3220859","volume":"322","author":"Tomiyama T.","year":"1997","unstructured":"Tomiyama T.; Kaneko H.; Kataoka K.; Asano S.; Endo N.; Rifampicin inhibits the toxicity of pre-aggregated amyloid peptides by binding to peptide fibrils and preventing amyloid-cell interaction. Biochem J  1997,322(3),859-865","journal-title":"Biochem J"},{"key":"ref=160","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/S0925-4439(00)00034-X","volume":"1502","author":"Findeis M.A.","year":"2000","unstructured":"Findeis M.A.; Approaches to discovery and characterization of inhibitors of amyloid \u03b2-peptide polymerization. Biochim Biophys Acta Mol Basis Dis  2000,1502(1),76-84","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"ref=161","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1021\/bp060353n","volume":"23","author":"Lieu V.H.","year":"2007","unstructured":"Lieu V.H.; Wu J.W.; Wang S.S.S.; Wu C.H.; Inhibition of amyloid fibrillization of hen egg-white lysozymes by rifampicin and p-benzoquinone. Biotechnol Prog  2007,23(3),698-706","journal-title":"Biotechnol Prog"},{"key":"ref=162","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1046\/j.1471-4159.2002.00904.x","volume":"81","author":"Ono K.","year":"2002","unstructured":"Ono K.; Hasegawa K.; Yoshiike Y.; Takashima A.; Yamada M.; Naiki H.; Nordihydroguaiaretic acid potently breaks down preformed Alzheimer\u2019s \u03b2\u2010amyloid fibrils in vitro. J Neurochem  2002,81(3),434-440","journal-title":"J Neurochem"},{"key":"ref=163","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.bbadis.2006.03.002","volume":"1762","author":"Ono K.","year":"2006","unstructured":"Ono K.; Hamaguchi T.; Naiki H.; Yamada M.; Anti-amyloidogenic effects of antioxidants: Implications for the prevention and therapeutics of Alzheimer\u2019s disease. Biochim Biophys Acta Mol Basis Dis  2006,1762(6),575-586","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"ref=164","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.brainresbull.2014.05.007","volume":"107","author":"Yulug B.","year":"2014","unstructured":"Yulug B.; Hanoglu L.; Kilic E.; Schabitz W.R.; RIFAMPICIN: An antibiotic with brain protective function. Brain Res Bull  2014,107,37-42","journal-title":"Brain Res Bull"},{"key":"ref=165","first-page":"82","volume":"22","author":"Tsolaki M.","year":"2019","unstructured":"Tsolaki M.; Future strategies of management of Alzheimer\u2019s Disease. The role of homotaurine. Hell J Nucl Med  2019,22,82-94","journal-title":"Hell J Nucl Med"},{"key":"ref=166","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.cell.2019.09.001","volume":"179","author":"Long J.M.","year":"2019","unstructured":"Long J.M.; Holtzman D.M.; Alzheimer disease: An update on pathobiology and treatment strategies. Cell  2019,179(2),312-339","journal-title":"Cell"},{"key":"ref=167","doi-asserted-by":"publisher","first-page":"614","DOI":"10.3389\/fneur.2020.00614","volume":"11","author":"Manzano S.","year":"2020","unstructured":"Manzano S.; Ag\u00fcera L.; Aguilar M.; Olazar\u00e1n J.; A review on tramiprosate (homotaurine) in Alzheimer\u2019s disease and other neurocognitive disorders. Front Neurol  2020,11,614","journal-title":"Front Neurol"},{"key":"ref=168","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.neurobiolaging.2006.02.015","volume":"28","author":"Gervais F.","year":"2007","unstructured":"Gervais F.; Paquette J.; Morissette C.; Krzywkowski P.; Yu M.; Azzi M.; Lacombe D.; Kong X.; Aman A.; Laurin J.; Szarek W.A.; Tremblay P.; Targeting soluble A\u03b2 peptide with Tramiprosate for the treatment of brain amyloidosis. Neurobiol Aging  2007,28(4),537-547","journal-title":"Neurobiol Aging"},{"key":"ref=169","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/1750-1326-2-17","volume":"2","author":"Santa-Maria I.","year":"2007","unstructured":"Santa-Maria I.; Hern\u00e1ndez F.; Del Rio J.; Moreno F.J.; Avila J.; Tramiprosate, a drug of potential interest for the treatment of Alzheimer\u2019s disease, promotes an abnormal aggregation of tau. Mol Neurodegener  2007,2(1),17","journal-title":"Mol Neurodegener"},{"key":"ref=170","doi-asserted-by":"publisher","first-page":"255","DOI":"10.3390\/md403255","volume":"4","author":"Kem W.","year":"2006","unstructured":"Kem W.; Soti F.; Wildeboer K.; LeFrancois S.; MacDougall K.; Wei D.Q.; Chou K.C.; Arias H.; The nemertine toxin anabaseine and its derivative DMXBA (GTS-21): Chemical and pharmacological properties. Mar Drugs  2006,4(3),255-273","journal-title":"Mar Drugs"},{"key":"ref=171","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1007\/s00424-018-2180-6","volume":"470","author":"Schaller S.J.","year":"2018","unstructured":"Schaller S.J.; Nagashima M.; Sch\u00f6nfelder M.; Sasakawa T.; Schulz F.; Khan M.A.S.; Kem W.R.; Schneider G.; Schlegel J.; Lewald H.; Blobner M.; Jeevendra Martyn J.A.; GTS-21 attenuates loss of body mass, muscle mass, and function in rats having systemic inflammation with and without disuse atrophy. Pflugers Arch  2018,470(11),1647-1657","journal-title":"Pflugers Arch"},{"key":"ref=172","first-page":"979","volume":"283","author":"Kem W.R.","year":"1997","unstructured":"Kem W.R.; Mahnir V.M.; Papke R.L.; Lingle C.J.; Anabaseine is a potent agonist on muscle and neuronal alpha-bungarotoxin-sensitive nicotinic receptors. J Pharmacol Exp Ther  1997,283(3),979-992","journal-title":"J Pharmacol Exp Ther"},{"key":"ref=173","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/S0091-3057(96)00354-1","volume":"57","author":"Briggs C.A.","year":"1997","unstructured":"Briggs C.A.; Anderson D.J.; Brioni J.D.; Buccafusco J.J.; Buckley M.J.; Campbell J.E.; Decker M.W.; Donnelly-Roberts D.; Elliott R.L.; Gopalakrishnan M.; Holladay M.W.; Hui Y.H.; Jackson W.J.; Kim D.J.B.; Marsh K.C.; O\u2019Neill A.; Prendergast M.A.; Ryther K.B.; Sullivan J.P.; Arneric S.P.; Functional characterization of the novel neuronal nicotinic acetylcholine receptor ligand GTS-21 in vitro and in vivo. Pharmacol Biochem Behav  1997,57(1-2),231-241","journal-title":"Pharmacol Biochem Behav"},{"key":"ref=174","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/S0006-8993(97)00536-2","volume":"768","author":"Meyer E.M.","year":"1997","unstructured":"Meyer E.M.; Tay E.T.; Papke R.L.; Meyers C.; Huang G.; de Fiebre C.M.; 3-[2,4-Dimethoxybenzylidene]anabaseine (DMXB) selectively activates rat \u03b17 receptors and improves memory-related behaviors in a mecamylamine-sensitive manner. Brain Res  1997,768(1-2),49-56","journal-title":"Brain Res"},{"key":"ref=175","doi-asserted-by":"publisher","first-page":"6014","DOI":"10.2174\/1381612820666140316130720","volume":"20","author":"Russo P.","year":"2014","unstructured":"Russo P.; Bufalo A.; Frustaci A.; Fini M.; Cesario A.; Beyond acetylcholinesterase inhibitors for treating Alzheimer\u2019s disease: \u03b17-nAChR agonists in human clinical trials. Curr Pharm Des  2014,20(38),6014-6021","journal-title":"Curr Pharm Des"},{"key":"ref=176","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.3390\/ijms20092313","volume":"20","author":"Andrade S.","year":"2019","unstructured":"Andrade S.; Ramalho M.J.; Loureiro J.A.; Pereira M.C.; Natural compounds for Alzheimer\u2019s disease therapy: A systematic review of preclinical and clinical studies. Int J Mol Sci  2019,20(9),2313","journal-title":"Int J Mol Sci"},{"key":"ref=177","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1016\/j.neuint.2011.08.013","volume":"59","author":"Alonso E.","year":"2011","unstructured":"Alonso E.; Vale C.; Vieytes M.R.; Laferla F.M.; Gim\u00e9nez-Llort L.; Botana L.M.; 13-Desmethyl spirolide-C is neuroprotective and reduces intracellular A\u03b2 and hyperphosphorylated tau in vitro. Neurochem Int  2011,59(7),1056-1065","journal-title":"Neurochem Int"},{"key":"ref=178","doi-asserted-by":"publisher","first-page":"279","DOI":"10.2174\/1567205011310030007","volume":"10","author":"Alonso E.","year":"2013","unstructured":"Alonso E.; Otero P.; Vale C.; Alfonso A.; Antelo A.; Gim\u00e9nez-Llort L.; Chabaud L.; Guillou C.; Botana L.M.; Benefit of 13-desmethyl spirolide C treatment in triple transgenic mouse model of Alzheimer disease: Beta-amyloid and neuronal markers improvement. Curr Alzheimer Res  2013,10(3),279-289","journal-title":"Curr Alzheimer Res"},{"key":"ref=179","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/S0045-6535(03)00207-8","volume":"52","author":"Gribble G.W.","year":"2003","unstructured":"Gribble G.W.; The diversity of naturally produced organohalogens. Chemosphere  2003,52(2),289-297","journal-title":"Chemosphere"},{"key":"ref=180","doi-asserted-by":"publisher","first-page":"2616","DOI":"10.3390\/md11072616","volume":"11","author":"Deng C.M.","year":"2013","unstructured":"Deng C.M.; Liu S.X.; Huang C.H.; Pang J.Y.; Lin Y.C.; Secondary metabolites of a mangrove endophytic fungus Aspergillus terreus (No. GX7-3B) from the South China Sea. Mar Drugs  2013,11(7),2616-2624","journal-title":"Mar Drugs"},{"key":"ref=181","doi-asserted-by":"publisher","first-page":"2982","DOI":"10.1007\/s13197-014-1329-3","volume":"52","author":"Lai Y.J.","year":"2015","unstructured":"Lai Y.J.; Omega-3 fatty acid obtained from Nannochloropsis oceanica cultures grown under low urea protect against Abeta-induced neural damage. J Food Sci Technol  2015,52(5),2982-2989","journal-title":"J Food Sci Technol"},{"key":"ref=182","doi-asserted-by":"publisher","first-page":"578","DOI":"10.3390\/md6040578","volume":"6","author":"Sangnoi Y.","year":"2008","unstructured":"Sangnoi Y.; Sakulkeo O.; Yuenyongsawad S.; Kanjana-opas A.; Ingkaninan K.; Plubrukarn A.; Suwanborirux K.; Acetylcholinesterase-inhibiting activity of pyrrole derivatives from a novel marine gliding bacterium, Rapidithrix thailandica. Mar Drugs  2008,6(4),578-586","journal-title":"Mar Drugs"},{"key":"ref=183","doi-asserted-by":"publisher","first-page":"539","DOI":"10.3109\/13880209.2013.850516","volume":"52","author":"Liu Y.W.","year":"2014","unstructured":"Liu Y.W.; Shi D.H.; Chen A.J.; Zhu Q.; Xu J.T.; Zhang X.X.; Acetylcholinesterase inhibition effects of marine fungi. Pharm Biol  2014,52(5),539-543","journal-title":"Pharm Biol"},{"key":"ref=184","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1055\/s-2004-815491","volume":"70","author":"Park I.H.","year":"2004","unstructured":"Park I.H.; Jeon, S.Y.; Lee, H.J.; Kim, S.I.; Song, K.S. A \u03b2-secretase (BACE1) inhibitor hispidin from the mycelial cultures of Phellinus linteus. Planta Med  2004,70(2),143-146","journal-title":"Planta Med"},{"key":"ref=185","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1159\/000350515","volume":"5","author":"de Kivit S.","year":"2013","unstructured":"de Kivit S.; Kraneveld A.D.; Knippels L.M.J.; van Kooyk Y.; Garssen J.; Willemsen L.E.M.; Intestinal epithelium-derived galectin-9 is involved in the immunomodulating effects of nondigestible oligosaccharides. J Innate Immun  2013,5(6),625-638","journal-title":"J Innate Immun"},{"key":"ref=186","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.foodchem.2011.08.047","volume":"131","author":"Cust\u00f3dio L.","year":"2012","unstructured":"Cust\u00f3dio L.; Justo T.; Silvestre L.; Barradas A.; Duarte C.V.; Pereira H.; Barreira L.; Rauter A.P.; Alber\u00edcio F.; Varela J.; Microalgae of different phyla display antioxidant, metal chelating and acetylcholinesterase inhibitory activities. Food Chem  2012,131(1),134-140","journal-title":"Food Chem"},{"key":"ref=187","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1016\/j.neuroscience.2011.06.085","volume":"193","author":"Chen Y.","year":"2011","unstructured":"Chen Y.; Yang C.; Wang Z.J.; Proteinase-activated receptor 2 sensitizes transient receptor potential vanilloid 1, transient receptor potential vanilloid 4, and transient receptor potential ankyrin 1 in paclitaxel-induced neuropathic pain. Neuroscience  2011,193,440-451","journal-title":"Neuroscience"},{"key":"ref=188","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.steroids.2015.09.012","volume":"104","author":"Harms H.","year":"2015","unstructured":"Harms H.; Kehraus, S.; Nesaei-Mosaferan, D.; Hufendieck, P.; Meijer, L.; K\u00f6nig, G.M. A\u03b2-42 lowering agents from the marine-derived fungus Dichotomomyces cejpii. Steroids  2015,104,182-188","journal-title":"Steroids"},{"key":"ref=189","doi-asserted-by":"publisher","first-page":"5369","DOI":"10.1007\/s11033-023-08397-2","volume":"50","author":"Singh L.","year":"2023","unstructured":"Singh L.; Kaur N.; Bhatti R.; Neuroprotective potential of biochanin-A and review of the molecular mechanisms involved. Mol Biol Rep  2023,50(6),5369-5378","journal-title":"Mol Biol Rep"},{"key":"ref=190","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s00792-014-0704-3","volume":"19","author":"Vester J.K.","year":"2015","unstructured":"Vester J.K.; Glaring M.A.; Stougaard P.; Improved cultivation and metagenomics as new tools for bioprospecting in cold environments. Extremophiles  2015,19(1),17-29","journal-title":"Extremophiles"},{"key":"ref=191","doi-asserted-by":"publisher","first-page":"15681","DOI":"10.1073\/pnas.252630999","volume":"99","author":"Zengler K.","year":"2002","unstructured":"Zengler K.; Toledo G.; Rapp\u00e9 M.; Elkins J.; Mathur E.J.; Short J.M.; Keller M.; Cultivating the uncultured. Proc Natl Acad Sci  2002,99(24),15681-15686","journal-title":"Proc Natl Acad Sci"},{"key":"ref=192","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1111\/j.1574-6968.2009.01623.x","volume":"295","author":"Song J.","year":"2009","unstructured":"Song J.; Oh H.M.; Cho J.C.; Improved culturability of SAR11 strains in dilution-to-extinction culturing from the East Sea, West Pacific Ocean. FEMS Microbiol Lett  2009,295(2),141-147","journal-title":"FEMS Microbiol Lett"},{"key":"ref=193","doi-asserted-by":"publisher","first-page":"6386","DOI":"10.1128\/AEM.01309-07","volume":"73","author":"Bollmann A.","year":"2007","unstructured":"Bollmann A.; Lewis K.; Epstein S.S.; Incubation of environmental samples in a diffusion chamber increases the diversity of recovered isolates. Appl Environ Microbiol  2007,73(20),6386-6390","journal-title":"Appl Environ Microbiol"},{"key":"ref=194","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.mimet.2007.12.009","volume":"72","author":"Gavrish E.","year":"2008","unstructured":"Gavrish E.; Bollmann A.; Epstein S.; Lewis K.; A trap for in situ cultivation of filamentous actinobacteria. J Microbiol Methods  2008,72(3),257-262","journal-title":"J Microbiol Methods"},{"key":"ref=195","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/j.tibtech.2012.05.007","volume":"30","author":"Pham V.H.T.","year":"2012","unstructured":"Pham V.H.T.; Kim J.; Cultivation of unculturable soil bacteria. Trends Biotechnol  2012,30(9),475-484","journal-title":"Trends Biotechnol"},{"key":"ref=196","doi-asserted-by":"publisher","first-page":"2445","DOI":"10.1128\/AEM.01754-09","volume":"76","author":"Nichols D.","year":"2010","unstructured":"Nichols D.; Cahoon N.; Trakhtenberg E.M.; Pham L.; Mehta A.; Belanger A.; Kanigan T.; Lewis K.; Epstein S.S.; Use of ichip for high-throughput in situ cultivation of \u201cuncultivable\u201d microbial species. Appl Environ Microbiol  2010,76(8),2445-2450","journal-title":"Appl Environ Microbiol"},{"key":"ref=197","doi-asserted-by":"publisher","first-page":"369","DOI":"10.3390\/md9030369","volume":"9","author":"Berrue F.","year":"2011","unstructured":"Berrue F.; Withers S.T.; Haltli B.; Withers J.; Kerr R.G.; Chemical screening method for the rapid identification of microbial sources of marine invertebrate-associated metabolites. Mar Drugs  2011,9(3),369-381","journal-title":"Mar Drugs"},{"key":"ref=198","first-page":"1161","volume":"80","author":"Butler M.S.","year":"2014","unstructured":"Butler M.S.; Fontaine F.; Cooper M.A.; Natural product libraries: Assembly, maintenance, and screening. Planta Med  2014,80(14),1161-1170","journal-title":"Planta Med"},{"key":"ref=199","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.crbiot.2020.09.001","volume":"2","author":"Ghareeb M.A.","year":"2020","unstructured":"Ghareeb M.A.; Tammam M.A.; El-Demerdash A.; Atanasov A.G.; Insights about clinically approved and Preclinically investigated marine natural products. CRBIOT  2020,2,88-102","journal-title":"CRBIOT"},{"key":"ref=200","first-page":"299","volume":"385","author":"Mayer A.M.S.","year":"2023","unstructured":"Mayer A.M.S.; Pierce M.; Reji M.; Wu A.C.; Jekielek K.K.; Le H.Q.; Howe K.; Butt M.; Seo S.; Newman D.J.; Glaser K.B.; Marine-derived pharmaceuticals in clinical trials in 2022. J Pharmacol Exp Ther  2023,385(S3),299","journal-title":"J Pharmacol Exp Ther"}],"container-title":["Central Nervous System Agents in Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0118715249269050231129103002","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/225712\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0118715249269050231129103002","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,30]],"date-time":"2024-07-30T18:58:31Z","timestamp":1722365911000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/225712\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":200,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0118715249269050231129103002","relation":{},"ISSN":["1871-5249"],"issn-type":[{"value":"1871-5249","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2023-08-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-09-18","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-10-31","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-05-29","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}